Intercept Pharmaceuticals, Inc. (ICPT)

Intercept Pharmaceuticals Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Year	2022	2021	2020	2019	2018
Net Income	221.82	-91.43	-274.88	-344.68	-309.24
Depreciation & Amortization	2.26	7.53	8.21	9.05	4.58
Share-Based Compensation	21.89	28.03	49.19	55.98	49.91
Other Operating Activities	-272.74	14.8	45.62	43.04	14.03
Operating Cash Flow	-26.78	-41.07	-171.86	-236.61	-240.71
Capital Expenditures	-0.57	-0.4	-3.89	-1.14	-0.17
Change in Investments	-100.82	71.12	166.71	-187.85	-47.9
Other Investing Activities	363.23	-	-	-	-
Investing Cash Flow	261.85	70.73	162.82	-188.99	-48.07
Share Issuance / Repurchase	1.68	-75.81	1.3	236.25	265.73
Debt Issued / Paid	-268.44	116.79	0	223.42	0
Other Financing Activities	-0.56	-39.87	-1.99	-2.16	-2.18
Financing Cash Flow	-267.32	1.12	-0.69	457.52	263.55
Exchange Rate Effect	-6.3	-2.02	0.61	-0.39	-1.53
Net Cash Flow	-38.55	28.76	-9.13	31.53	-26.77
Free Cash Flow	-27.35	-41.46	-175.76	-237.75	-240.88
Free Cash Flow Margin	-9.57%	-15.90%	-75.12%	-94.34%	-133.97%
Free Cash Flow Per Share	-0.81	-1.30	-5.33	-7.51	-8.46

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).